Straits Times Index
3,212.77 +21.61 (+0.68%) Nikkei
26,587.74 +40.69 (+0.15%) Hang Seng
20,265.10 +314.89 (+1.58%) FTSE 100
7,464.80 +46.65 (+0.63%) BTC-USD
29,896.00 -850.87 (-2.77%) CMC Crypto 200
669.98 +427.30 (+176.08%)
Sesen Bio, Inc. (SESN)
After hours:
- Zacks
CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs
While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.
- Zacks
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
- Business Wire
Sesen Bio Reports First Quarter 2022 Financial Results and Business Update
CAMBRIDGE, Mass., May 09, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2022. During the quarter, the Company continued to engage with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for Vicineum™ for the treatment
